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ity 58%, the positive and the negative predictive values 
79 and 78%, respectively. With a cut-off of 4.0 ng/ml for 
total PSA, the sensitivity was 87%, the specifi city 59%, 
the positive and the negative predictive values were 78 
and 72%, respectively.  Conclusions: There was a statisti-
cally signifi cant advantage for complexed PSA com-
pared to total PSA in the discrimination between BPH 
and prostate cancer. The difference was, however, small 
and its clinical relevance is questionable. 
 Copyright © 2006 S. Karger AG, Basel 
 Introduction 
 Prostate-speciﬁ c antigen (PSA) determination is of 
paramount importance in the diagnosis and management 
of prostate cancer  [1] . Several studies suggested that the 
measurement of PSA bound to serum proteins (com-
plexed PSA) might improve the performance of PSA test-
ing in the discrimination between benign and malignant 
prostatic conditions  [2–5] . The aim of this study was to 
investigate whether the substitution of total PSA testing 
by measurement of complexed PSA may represent an ad-
vantage in clinical practice. 
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 Abstract 
 Background: To compare the clinical value of the mea-
surement of complex and total PSA in the discrimination 
between benign prostatic hyperplasia (BPH) and pros-
tate cancer.  Methods: In serum samples collected from 
166 men with histopathologically proven clinically local-
ized prostate cancer and of 97 men with BPH, total pros-
tate-specifi c antigen (PSA), complexed PSA and the free 
to total PSA ratio were determined. The statistical analy-
sis was done by the comparison of the receiver operator 
characteristic (ROC) curves.  Results: The areas under the 
ROC curves were 0.776 for total PSA, 0.799 for com-
plexed PSA (total PSA vs. cPSA: p  ! 0.0001) and 0.812 
for the free to total PSA ratio. With a cut-off of 3.0 ng/ml 
for complexed PSA, the sensitivity was 90%, the specifi c-
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 Materials and Methods 
 Serum samples were obtained from 166 men with histopatho-
logically proven clinically localized prostate cancer prior to radical 
prostatectomy and of 97 men with benign prostatic hyperplasia 
(BPH) prior to transurethral or transvesical surgery of the prostate. 
The latter patients had no evidence of malignancy in their resection 
specimens. Patients with a history of neoadjuvant androgen depri-
vation were not included into this study. The mean age was 65 years 
(range 48–78 years) among the cancer patients and 69 years (range 
45–84 years) in the BPH patients (p  ! 0.0001). The serum samples 
were processed immediately after collection and stored no longer 
than 8 h at 4  °  C before being frozen at –80  °  C. In all samples, total 
PSA (Abbott AxSym Total PSA, Abbott, Wiesbaden, Germany), 
the free to total PSA ratio (Abbott AxSym Free PSA) and the com-
plexed PSA (Bayer Diagnostics, Fernwald, Germany) were deter-
mined. The statistical analysis was done by the comparison of the 
receiver operator characteristic (ROC) curves  [6] . p values are raw 
values. 
 Results 
 The mean value of total PSA was 10.6 ng/ml (range 
0.2–61 ng/ml) in the prostate cancer and 5.1 ng/ml (range 
0.3–35 ng/ml) in the BPH group (p  ! 0.0001). The mean 
value of complexed PSA was 9.3 ng/ml (range 0.2–
59 ng/ml) in the cancer patients and 4.0 ng/ml (range 
0.2–27 ng/ml) in BPH patients (p  ! 0.0001). The mean 
free to total PSA ratio was 14% (range 2.5–38%) in can-
cer patients and 23% (range 6.3–47%) in the BPH pa-
tients (p  ! 0.0001).  The ROC curves for total and com-
plexed PSA and for the free to total PSA ratio are shown 
in  ﬁ gure 1 . The areas under the ROC curves (AUC) were 
0.776 for total PSA, 0.799 for complexed PSA and 0.812 
for the free to total PSA ratio. The ROC curves for total 
PSA and complexed PSA differed signiﬁ cantly ( ﬁ g. 1 ; 
p  ! 0.0001). There were no signiﬁ cant differences be-
tween the ROC curves for total PSA and the free to total 
PSA ratio (p = 0.07) and for complexed PSA and the free 
to total PSA ratio (p = 0.25). At a sensitivity level of 95%, 
threshold values of 2.0 ng/ml for complexed PSA, 2.5 ng/
ml for total PSA and 10% for the free to total PSA ratio 
were obtained. The ﬁ gures for sensitivity, speciﬁ city, 
positive and negative predictive values for the 95% 
thresholds and for cut-off-values of 3 and 4 ng/ml are 
given in  table 1 , corresponding ﬁ gures for the total PSA 
grey zone of 2–10 ng/ml are shown in  table 2 . In the total 
PSA grey zone between 2 and 10 ng/ml, the following 
AUC values were obtained: 0.723 for complexed PSA, 
0.673 for total PSA (p  ! 0.0001 for the comparison of the 
ROC curves of total and complexed PSA) and 0.795 for 
the free to total PSA ratio (p  ! 0.01 for the comparison 
of the ROC curves of total and of the free to total PSA 
ratio). The comparison between the ROC curves of com-
plexed PSA and the free to total PSA ratio narrowly failed 
the signiﬁ cance level (p = 0.05). The ROC curves in the 
total PSA grey zone between 2 and 10 ng/ml are shown 
in  ﬁ gure 2 .  
 Discussion 
 Complexed PSA has been suggested to be a superior 
initial test in the detection of prostate cancer  [2–5] . The 
measurement of complexed PSA instead of total PSA has 
been found to be able to reduce the number of unneces-
sary biopsies  [5, 7] . Other authors, however, questioned 
the clinical relevance of the statistically detectable advan-
tage of complexed PSA  [8] . Patients with an elevated PSA 
referred for surgical treatment of BPH represent a com-
Table 1. Sensitivity, speciﬁ city, positive and negative predictive 
value for different complexed (cPSA) and total PSA (tPSA) and free 
to total PSA ratio (%fPSA) thresholds in the whole study popula-
tion
Threshold Sensi-
tivity, %
Speci-
ﬁ city, %
Predictive value, %1
positive negative
cPSA 2.0 ng/ml 95 44 75 84
tPSA 2.5 ng/ml 95 44 75 84
%fPSA 28% 95 29 70 78
cPSA 3.0 ng/ml 90 58 79 78
tPSA 4.0 ng/ml 87 59 78 72
1 Valid for a prevalence of 63%.
Table 2. Sensitivity, speciﬁ city, positive and negative predictive 
value for different complexed (cPSA) and total PSA (tPSA) and free 
to total PSA ratio (%fPSA) thresholds in the total PSA range of 
2–10 ng/ml
Threshold Sensi-
tivity, %
Speci-
ﬁ city, %
Predictive value, %1
positive negative
cPSA 2.0 ng/ml 95 16 70 62
tPSA 2.5 ng/ml 95 16 70 62
%fPSA 28% 95 31 74 75
cPSA 3.0 ng/ml 87 43 76 62
tPSA 4.0 ng/ml 81 45 75 54
1 Valid for a prevalence of 68%.
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mon problem in the setting of a hospital. In this popula-
tion, it can be difﬁ cult to decide whether a prostate bi-
opsy should precede surgical treatment of BPH. There-
fore, we choose such patients for comparison with 
candidates for radical prostatectomy to evaluate the use-
fulness of the complexed PSA assay. Compared with mul-
tiple studies involving patients with positive and negative 
prostate biopsies  [2, 4, 5, 8–15] , in our study, the AUCs 
were higher for all PSA derivatives (indicating a better 
discrimination between benign and malignant prostatic 
conditions by the determination of PSA-related labora-
tory values). A selection effect might be a possible expla-
nation for this phenomenon. It has been suggested that 
several ratios of PSA-related laboratory values may im-
prove the discrimination between benign and malignant 
prostatic conditions  [2, 11, 13] . The results were, how-
ever, inconsistent  [11] , and it is questionable whether one 
of the suggested ratios will gain general acceptance  [16, 
17] . Therefore, we dispensed with the analysis of ratios 
other than the free to total PSA ratio in this study. Com-
pared to ROC curves, deﬁ nite cut-off values are likely to 
be preferred in the clinical setting. Some authors report 
rather arbitrary cut-off values for complexed and total 
PSA (for instance 2.9 ng/ml for complexed PSA and 
3.9 ng/ml for total PSA representing the 93rd sensitivity 
percentile  [3] or 2.9 for complexed PSA and 4.0 ng/ml for 
total PSA representing the 90th sensitivity percentile in 
their studies  [12] ) or a broad range of possible cut-off val-
ues for complexed PSA  [2] . Other authors used the 95th 
sensitivity percentile to deﬁ ne cut-off values and obtained 
differing results  [8, 9] . We considered two pairs of cut-off 
values suitable for clinical application, the 95% sensitiv-
ity threshold (in this study 2.0 ng/ml for complexed and 
2.5 ng/ml for total PSA) and 3.0 ng/ml for complexed PSA 
and 4.0 for total PSA in agreement with values suggested 
by others  [3, 12] and with the most commonly used total 
PSA threshold of 4.0 ng/ml. At these cut-offs, there was 
no appreciable difference in the performance of the com-
plexed and total PSA tests in our study reﬂ ected by the 
associated speciﬁ city and positive and negative predic-
tive values.  
 This study has several limitations. Since patients with 
symptomatic BPH, partially at advanced age, were in-
cluded as a cohort with a benign prostatic condition, the 
results may not necessarily apply to a screening popula-
tion. Patients with BPH were in average four years older 
than those with prostate cancer. There was, however, only 
a weak and non-signiﬁ cant trend towards higher com-
plexed and total PSA values with increasing age (data not 
shown). Furthermore, transrectal prostate biopsy is not 
entirely equivalent to transurethral (or transvesical) re-
section of the prostate in the veriﬁ cation or ruling out of 
prostate cancer. The described limitations are, however, 
not likely to interfere meaningfully with the interpreta-
tion of the study results.  
 Fig. 2. Receiver operator characteristic curves for complexed PSA, 
total PSA and the free to total PSA ratio in the discrimination be-
tween benign prostate hyperplasia and prostate cancer in the total 
PSA range of 2–10 ng/ml. 
 Fig. 1. Receiver operator characteristic curves for complexed PSA, 
total PSA and the free to total PSA ratio in the discrimination be-
tween benign prostate hyperplasia and prostate cancer in the whole 
study population.  
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 In summary, in the discrimination of BPH and pros-
tate cancer, complexed PSA added little information to 
the conventional approach with determination of total 
PSA and the consideration of the free to total PSA ratio 
in cases of uncertainty. Even if complexed and total PSA 
were considered alone (and the free to total PSA ratio is 
ignored) and even if only the total PSA grey zone of 2–
10 ng/ml was considered, the statistically signiﬁ cant ad-
vantage for complexed PSA was too small to be of clinical 
relevance in the setting of this study ( tables 1 ,  2 ). 
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